Technical Updates, New Product Installation, and Financial Results - Analyst Notes on Abbott, Stryker, Varian, Align Technology and Cooper

Fri Jun 13, 2014 6:20am EDT

* Reuters is not responsible for the content in this press release.

Technical Updates, New Product Installation, and Financial Results - Analyst Notes on Abbott, Stryker, Varian, Align Technology and Cooper

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 13, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Abbott Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), Varian Medical Systems, Inc. (NYSE: VAR), Align Technology, Inc. (NASDAQ: ALGN) and The Cooper Companies, Inc. (NYSE: COO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3707-100free.

--
Abbott Laboratories Analyst Notes
On June 10, 2014, shares of Abbott Laboratories (Abbott) gained 1.0% to close at $40.53. Over the previous five-day trading sessions, Abbott's shares increased by 1.30% compared to the Dow Jones Industrial Average which gained 1.37% during the same period. The full analyst notes on Abbott are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/ABT/report.pdf

--
Stryker Corporation Analyst Notes
On June 10, 2014, Stryker Corporation's (Stryker) stocks closed trading at $85.10, reflecting a slight drop by 0.47%. Over the past month of trading, Stryker's stocks increased 5.56% while the S&P 500 also increased by 3.85% over the same period. The full analyst notes on Stryker are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/SYK/report.pdf

--
Varian Medical Systems, Inc. Analyst Notes
On June 2, 2014, Varian Medical Systems, Inc. (Varian) reported that its TrueBeam™ STx system has been installed at the Community Cancer Center in Norman, Illinois. According to Varian, the TrueBeam STx system targets tumors with great speed and accuracy, including tumors that move during treatment as the patient breathes. Varian informed that the system features technical innovations that synchronize imaging, patient positioning, motion management, and quicker treatment delivery. Shermian Woodhouse, M.D., Radiation Oncologist and Cancer Center Medical Director, commented, "Having the TrueBeam STx makes it possible for us to offer more varied treatment options to a wider range of patients. The system also offers us more tools for ensuring and documenting the accuracy of treatments. From the perspective of our staff, it has enabled a significant improvement to our workflow. Since it was installed, I've seen an increase in staff morale. Our people know that the Cancer Center is dedicated to providing them with the tools they need to do their jobs really well." The full analyst notes on Varian are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/VAR/report.pdf

--
Align Technology, Inc. Analyst Notes
On June 10, 2014, shares of Align Technology, Inc. (Align Technology) reflected a 1.28% decrease, closing at $52.47. Over the previous month's trading session, Align Technology's shares increased 6.11% while the Nasdaq Composite gained 6.54% during the same period. The full analyst notes on Align Technology are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/ALGN/report.pdf

--
The Cooper Companies, Inc. Analyst Notes
On June 5, 2014, The Cooper Companies, Inc. (Cooper) announced its Q2 FY 2014 financial results (period ended April 30, 2014). For the quarter, the Company registered total net sales of $412.3 million, up 7.4% YoY. Q2 FY 2014 net income was at $79.6 million or $1.62 per diluted share, compared with $75.1 million or $1.52 per diluted share in Q2 FY 2013. Cooper has also revised its FY 2014 guidance, with a total revenues range from $1.68 billion to $1.72 billion and EPS range from $6.78 to $7.00. The full analyst notes on Cooper are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/COO/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.